SecBot SecBot

HRMY

Harmony Biosciences Holdings, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001802665 Biotech & Drug Discovery
$32.96 −0.80 (−2.37%)
Nov 16 4:00 PM ET · prev $33.76
Market cap
$2.0B
Small cap
Consensus
Buy
72% Buy or better · 18 analysts
Median target
$49.50
+50% · range $32.00–70.00
1 year
−3.0%
from $33.99 · Nov 17
30 days
−12.2%
from $37.54
52-week range
$26.54–42.86
−23% from high · low Mar 27
Avg volume 20D
1.20M
shares / day
Short interest
6.66M
≈11.3% of shares · +23.1%
Days to cover
5.6
at average volume
Insider net
−$3.1M
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
19
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 2 bearish · 0 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next FDA decision date, Mar 31, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $3.1M.

  • InstitutionsBULLISH

    Q3 2026: 36 added (0 new), 18 trimmed or exited.

  • AnalystsBULLISH

    13 of 18 rate it Buy or better. Median target $49.50 (+50%).

  • Short sellersBUILDING

    Short interest +23.1% to 6.66M shares. 5.6 days to cover, ≈11.3% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 7.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Allspring Global Investments Holdings, LLCDOUBLED1,124,717$44.5M
Invesco Ltd.ADD699,607$27.5M
Boston PartnersDOUBLED423,647$16.6M
PRINCIPAL FINANCIAL GROUP INCADD362,218$14.2M
FRANKLIN TEMPLETON INCADD294,448$10.1M
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED257,946$10.1M
Creative PlanningADD119,028$4.7M
HRT FINANCIAL LPTRIM72,061$2.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 72% rate it Buy or better
Strong Buy5Buy8Hold4Sell1Strong Sell0
12-month targets · 12 analysts

Price is inside the target range. Median implies +50%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 19, 2026Needham
REITERATE
REITERATEBuy
Oct 13, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 12, 2026Needham
REITERATE
REITERATEBuy
Aug 26, 2026Wolfe Research
INITIATE
INITIATEOutperform
Aug 5, 2026Truist Securities
MAINTAIN
MAINTAINHold

Insider ledger

Form 4
$0
bought · 0 insiders
$3.1M
sold · 1 insider
DateInsiderTypeValue
Sep 18, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 18, 2026
EXERCISE$319.4K
Sep 18, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 18, 2026
EXERCISE$770.3K
Sep 18, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 18, 2026
SELL$1.5M
Sep 17, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 17, 2026
EXERCISE$12.1K
Sep 17, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 17, 2026
EXERCISE$12.3K
Sep 17, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 17, 2026
SELL$34.4K
Sep 16, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 16, 2026
EXERCISE$27.6K
Sep 16, 2026
Budur Kumar
CHIEF MEDICAL OFFICER
Sep 16, 2026
EXERCISE$27.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
6,664,944
shares short
+23.1%
vs prior settlement
5.6
days to cover
≈11.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 4, 2026 SEC
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), missing consensus of $272.1M, and GAAP…
8-K · Impact 5/10
Nov 4, 2026 SEC
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), slightly below the $272.1M consensus…
PRESS-RELEASE · Impact 5/10
Nov 4, 2026 Earnings
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the
Oct 1, 2026 Press
Harmony Biosciences announced a poster presentation at the 17th European Narcolepsy Days featuring data from its…
Impact 3/10
Sep 30, 2026 Inst.
Allspring Global Investments Holdings, · DOUBLED
1,124,717 shares ($44.5M)
Sep 30, 2026 Inst.
Invesco Ltd. · ADD
699,607 shares ($27.5M)
Sep 18, 2026 Insider
Budur Kumar acquired via exercise 10,406 shares
CHIEF MEDICAL OFFICER @ $30.69 ($319.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

SecBot reports

19 filings · 1 press release · 3 bullish · 4 bearish · 2 mixed · 10 neutral
All HRMY filing & press-release reports (20)